🇺🇸 FDA
Pipeline program

PEG-IFN alfa-2a

ML17908

Approved small_molecule completed

Quick answer

PEG-IFN alfa-2a for Hepatitis C, Chronic is a Approved program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Hepatitis C, Chronic
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials